Radiation Therapy Combined with (or Without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2009 Aug 19

PMID 19688124

Citations 13

Authors

Yeon-Sil Kim

Bum-Soo Kim

So-Lyoung Jung

Yeon-Soo Lee

Min-Sik Kim

Dong-Il Sun

Eun-Jung Yoo

Seong-Kwon Mun

Sei-Chul Yoon

Su-Mi Chung

Hoon-Kyo Kim

Seung-Ho Jo

Jin-Hyoung Kang

Affiliations

Soon will be listed here.

Abstract

Purpose: This retrospective study was carried out to evaluate the efficacy and toxicity of radiation therapy (RT) with/without cisplatin-based chemotherapy in nasopharyngeal cancer (NPC).

Materials And Methods: One hundred forty six patients with NPC received curative RT and/or cisplatin-based chemotherapy. Thirty-nine patients were treated with induction chemotherapy (IC), including cisplatin and 5-fluorouracil followed by RT. Another 63 patients were treated with concurrent chemoradiotherapy (CCRT) using cisplatin, and 22 patients were treated with IC followed by CCRT. The remaining 22 patients were treated with RT alone.

Results: One hundred four (80.0%) patients achieved complete response (CR), and 23 (17.7%) patients achieved partial response (PR). The patterns of failure were: locoregional recurrences in 21.2% and distant metastases in 17.1%. Five-year overall survival (OS) and progression free survival (PFS) were 50.7% and 45.0%, respectively. Multivariate Cox stepwise regression analysis revealed CR to chemoradiotherapy to be a powerful prognostic factor for OS. CR to chemoradiotherapy and completion of radiation according to the time schedule were favorable prognostic factors for PFS. A comparison of each treatment group (IC --> RT vs. CCRT vs. IC --> CCRT vs. RT alone) revealed no significant differences in the OS or PFS. However, subgroup analysis showed significant differences in both OS and DFS in favor of the combined chemoradiotherapy group compared with RT alone, for stage IV and T3-4 tumors. Grade 3-4 toxicities were more common in the combined chemoradiotherapy arm, particularly in the CCRT group.

Conclusions: This study was limited in that it was a retrospective study, much time was required to collect patients, and there were imbalances in the number of patients in each treatment group. Combined chemoradiotherapy remarkably prolonged the OS and PFS in subgroup patients with stage IV or T3-4 NPC.

Citing Articles

SEPT9, H4C6, and RASSF1A methylation in nasopharyngeal swabs: A reflection of potential minimally invasive biomarkers for early screening of nasopharyngeal cancer.

Qian T, Zhou Z, Zhang Q, Liou Y, Zhou H Medicine (Baltimore). 2023; 102(50):e36583.

PMID: 38115290 PMC: 10727677. DOI: 10.1097/MD.0000000000036583.

MicroRNA-145-5p modulates Krüppel-like factor 5 and inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma.

Yuan C, Hsu W, Huang A, Yuan B, Chen I, Hsu C BMC Mol Cell Biol. 2022; 23(1):28.

PMID: 35836107 PMC: 9284881. DOI: 10.1186/s12860-022-00430-9.

Inhibition of PAD4 enhances radiosensitivity and inhibits aggressive phenotypes of nasopharyngeal carcinoma cells.

Chen H, Luo M, Wang X, Liang T, Huang C, Huang C Cell Mol Biol Lett. 2021; 26(1):9.

PMID: 33726680 PMC: 7962337. DOI: 10.1186/s11658-021-00251-2.

DNA methylation biomarkers for nasopharyngeal carcinoma.

Han B, Yang X, Zhang P, Zhang Y, Tu Y, He Z PLoS One. 2020; 15(4):e0230524.

PMID: 32271791 PMC: 7144954. DOI: 10.1371/journal.pone.0230524.

MicroRNA-432 Suppresses Invasion and Migration via E2F3 in Nasopharyngeal Carcinoma.

Wang T, Du M, Zhang W, Bai H, Yin L, Chen W Onco Targets Ther. 2020; 12:11271-11280.

PMID: 31908492 PMC: 6927591. DOI: 10.2147/OTT.S233435.

References

Vikram B, Mishra U, Strong E, Manolatos S . Patterns of failure in carcinoma of the nasopharynx: I. Failure at the primary site. Int J Radiat Oncol Biol Phys. 1985; 11(8):1455-9. DOI: 10.1016/0360-3016(85)90332-3. View

Chua D, Sham J, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S . Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal.... Cancer. 1998; 83(11):2270-83. View

Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M . Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol. 1988; 6(9):1401-10. DOI: 10.1200/JCO.1988.6.9.1401. View

Boussen H, Cvitkovic E, Wendling J, Azli N, Bachouchi M, Mahjoubi R . Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. J Clin Oncol. 1991; 9(9):1675-81. DOI: 10.1200/JCO.1991.9.9.1675. View

Lin J, Jan J, Hsu C, Liang W, Jiang R, Wang W . Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003; 21(4):631-7. DOI: 10.1200/JCO.2003.06.158. View

Lee A, Poon Y, Foo W, Law S, Cheung F, Chan D . Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992; 23(2):261-70. DOI: 10.1016/0360-3016(92)90740-9. View

Chan A, Teo P, Ngan R, Leung T, Lau W, Zee B . Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002; 20(8):2038-44. DOI: 10.1200/JCO.2002.08.149. View

Kim T, Ko Y, Lee M, Kim B, Chung S, Yoo I . Treatment outcome of cisplatin-based concurrent chemoradiotherapy in the patients with locally advanced nasopharyngeal cancer. Cancer Res Treat. 2009; 40(2):62-70. PMC: 2697486. DOI: 10.4143/crt.2008.40.2.62. View

Teo P, Yu P, Lee W, Leung S, Kwan W, Yu K . Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys. 1996; 36(2):291-304. DOI: 10.1016/s0360-3016(96)00323-9. View

10.

Altun M, Fandi A, Dupuis O, Cvitkovic E, KRAJINA Z, Eschwege F . Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys. 1995; 32(3):859-77. DOI: 10.1016/0360-3016(95)00516-2. View

11.

Tan E, Chua E, Wee J, Tan T, Fong K, Ang P . Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results. Int J Radiat Oncol Biol Phys. 1999; 45(3):597-601. DOI: 10.1016/s0360-3016(99)00210-2. View

12.

Bachaud J, Cohen-Jonathan E, Alzieu C, David J, Serrano E, Daly-Schveitzer N . Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996; 36(5):999-1004. DOI: 10.1016/s0360-3016(96)00430-0. View

13.

Kwong D, Sham J, Choy D . The effect of loco-regional control on distant metastatic dissemination in carcinoma of the nasopharynx: an analysis of 1301 patients. Int J Radiat Oncol Biol Phys. 1994; 30(5):1029-36. DOI: 10.1016/0360-3016(94)90306-9. View

14.

. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on.... Int J Radiat Oncol Biol Phys. 1996; 35(3):463-9. DOI: 10.1016/s0360-3016(96)80007-1. View

15.

Al-Sarraf M, LeBlanc M, Giri P, Fu K, Cooper J, Vuong T . Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16(4):1310-7. DOI: 10.1200/JCO.1998.16.4.1310. View

16.

Chan A, Teo P, Leung T, Leung S, Lee W, Yeo W . A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995; 33(3):569-77. DOI: 10.1016/0360-3016(95)00218-N. View

17.

Huncharek M, Kupelnick B . Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol. 2002; 25(3):219-23. DOI: 10.1097/00000421-200206000-00002. View

18.

Baujat B, Audry H, Bourhis J, Chan A, Onat H, Chua D . Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2005; 64(1):47-56. DOI: 10.1016/j.ijrobp.2005.06.037. View

19.

Ali H, Al-Sarraf M . Chemotherapy in advanced nasopharyngeal cancer. Oncology (Williston Park). 2000; 14(8):1223-30; discussion 1232-7, 1239-42. View

20.

Lee A, Lau W, Tung S, Chua D, Chappell R, Xu L . Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005; 23(28):6966-75. DOI: 10.1200/JCO.2004.00.7542. View